
Thymosin Alpha-1
Thymosin alpha-1 has real human trial data, mostly from outside the US, but the largest and best-designed trials were negative: it did not lower 28-day deaths in 1,089 adults with sepsis or prevent infected pancreatic necrosis in 508 patients with severe pancreatitis. Smaller studies in hepatitis B, cancer and COVID-19 suggest possible benefits that have not been confirmed. It is not approved in the US.
Research compound: not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.
Quick decision guide
May help most
No one outside a clinical trial in the US. In trials it has been studied in adults with chronic hepatitis B, sepsis, severe pancreatitis, some cancers and COVID-19
Common dosing range
No approved or established dose in the US. Trials gave 1.6 mg by injection under the skin, for example every 12 hours for 7 days in hospital studies, under medical supervision
When to expect effects
Not established; in hepatitis B trials the response tended to appear months after the 6-month course ended
Watch out for
Not FDA-approved and cannot be prescribed as an approved medicine in the US. Products sold online, including "research" vials, are unapproved and unverified, and FDA has said compounded thymosin alpha-1 may pose a significant risk of immune reactions (immunogenicity) and has complexities with peptide-related impurities, with inadequate safety information
What is it
Thymosin alpha-1 (thymalfasin) is not an FDA-approved drug and not a dietary supplement: Drugs@FDA lists no approved product that contains it, and any vial sold online as "thymosin alpha-1" or "TA-1", including products labeled for research, is unapproved and of unverified purity and strength. It is a synthetic 28-amino-acid peptide, a synthetic version of an immune signaling substance first found in the thymus; in trials it is given by injection under the skin. Outside the US it has been sold under the brand name Zadaxin: a 2002 drug-profile review listed approvals for chronic hepatitis B (and in some countries hepatitis C) in places including China, India, Mexico, Argentina, Peru, the Philippines, Singapore, Thailand and Venezuela, and a 2009 review by a researcher involved in its development said it was approved in over 35 countries. These are older reviews, not a current list, and we could not confirm which approvals are in force today on any regulator's website. In the US it has only been tested in clinical trials, including a phase 1 study, still recruiting in 2026, of whether it boosts COVID-19 vaccine responses in adults aged 65 and older (NCT06821100).
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
sepsis Good Evidence | None in the largest trial (23.4% vs 24.1% died by day 28) | Not established; possible subgroup effects (for example in diabetes or cancer) need their own trials | Measured at 28 days |
severe acute necrotizing pancreatitis Good Evidence | None significant (15.7% vs 18.1% developed infected necrosis) | Not established | Measured during the hospital stay |
chronic hepatitis B Limited Evidence | Delayed; better virological and liver enzyme responses 6 months after stopping than interferon, not during treatment | Adults with chronic hepatitis B in older trials, mostly HBeAg-negative | Responses appeared after the 6-month course ended |
cancer, alongside chemotherapy Limited Evidence | Uncertain; trends toward longer survival that were not statistically significant | Adults with cancer in clinical trials, alongside standard treatment | Measured over 12 to 24 months in the melanoma trial |
COVID-19 Mixed Evidence | Uncertain; lower mortality in pooled, highly inconsistent studies | Hospitalized adults with moderate to critical COVID-19 in the studies pooled | Measured during hospital treatment |
sepsis
- Effect
- None in the largest trial (23.4% vs 24.1% died by day 28)
- Best fit
- Not established; possible subgroup effects (for example in diabetes or cancer) need their own trials
- Time
- Measured at 28 days
severe acute necrotizing pancreatitis
- Effect
- None significant (15.7% vs 18.1% developed infected necrosis)
- Best fit
- Not established
- Time
- Measured during the hospital stay
chronic hepatitis B
- Effect
- Delayed; better virological and liver enzyme responses 6 months after stopping than interferon, not during treatment
- Best fit
- Adults with chronic hepatitis B in older trials, mostly HBeAg-negative
- Time
- Responses appeared after the 6-month course ended
cancer, alongside chemotherapy
- Effect
- Uncertain; trends toward longer survival that were not statistically significant
- Best fit
- Adults with cancer in clinical trials, alongside standard treatment
- Time
- Measured over 12 to 24 months in the melanoma trial
COVID-19
- Effect
- Uncertain; lower mortality in pooled, highly inconsistent studies
- Best fit
- Hospitalized adults with moderate to critical COVID-19 in the studies pooled
- Time
- Measured during hospital treatment
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
sepsis
No benefit foundIn the TESTS trial, a double-blind, placebo-controlled phase 3 study at 22 centers in China, 1,106 adults aged 18 to 85 with sepsis were randomly assigned to thymosin alpha-1 1.6 mg or placebo injections every 12 hours for 7 days, and 1,089 who received at least one dose were analyzed. Deaths from any cause by day 28 were 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.97 after a 2025 correction of the trial data), and no secondary or safety outcome differed. Subgroup results hinted at differences by age and diabetes, but these were exploratory. The trial was funded by Sun Yat-sen University, a Guangdong research center and SciClone Pharmaceuticals, which sells thymosin alpha-1. A 2025 meta-analysis of 11 trials found fewer deaths overall (odds ratio 0.73), yet no benefit when it was limited to high-quality or multicenter trials.
Bottom line: In the largest, best-designed trial, thymosin alpha-1 did not help adults with sepsis survive.
Evidence is mixed
A 2025 meta-analysis of 11 randomized trials reported lower 28-day mortality overall, but the benefit disappeared in high-quality and multicenter trials, and the authors said the total number of patients studied is still too small.
severe acute necrotizing pancreatitis
No benefit foundIn a double-blind, placebo-controlled trial at several Chinese centers, 508 patients with predicted severe acute necrotizing pancreatitis (94.3% needed intensive care) received thymosin alpha-1 1.6 mg every 12 hours for 7 days and then once daily for 7 days, or placebo. Infection of the dead pancreatic tissue, the main outcome, occurred in 15.7% versus 18.1%, a difference that was not statistically significant. New organ failure, bleeding and fistula rates also did not differ. Several authors reported fees from SciClone Pharmaceuticals.
Bottom line: Thymosin alpha-1 did not prevent infection in severe pancreatitis.
chronic hepatitis B
Biomarker supportA 2008 meta-analysis pooled 4 small randomized trials (199 patients, mostly HBeAg-negative) comparing thymosin alpha-1 with interferon alpha for 6 months. At the end of treatment, thymosin alpha-1 did no better and on the combined response measure did worse (odds ratio 0.54). Six months after treatment stopped, responses favored thymosin alpha-1 (odds ratio 3.71 for virological response and 2.69 for complete response). The trials were small and are older than today's standard oral antiviral drugs, which were not the comparison.
Bottom line: Small older trials suggest a delayed effect in hepatitis B; it has not been tested against today's standard drugs.
cancer, alongside chemotherapy
Disease adjunctA 2011 Cochrane review found 6 trials of synthetic thymic peptides (thymopentin or thymosin alpha-1) added to chemotherapy or radiotherapy in adults with cancer. For thymosin alpha-1, the pooled result showed a trend toward fewer deaths that was not statistically significant (risk ratio 1.21 for survival, P = 0.14), and most trials had at least a moderate risk of bias. In the largest single trial, 488 people with metastatic melanoma were randomly assigned to five groups, all given dacarbazine chemotherapy: thymosin alpha-1 at 1.6, 3.2 or 6.4 mg with interferon alfa, thymosin alpha-1 at 3.2 mg without interferon, or interferon alfa alone (the control group). The two 3.2 mg groups had 10 and 12 tumor responses versus 4 in the control group. Median survival was 9.4 months in all patients given thymosin alpha-1 versus 6.6 months in the control group, a difference that did not reach statistical significance (hazard ratio 0.80, P = 0.08).
Bottom line: Possible but unproven help alongside chemotherapy; trials have not shown a clear survival benefit.
COVID-19
Disease adjunctA 2023 meta-analysis pooled 8 studies of adults hospitalized with moderate to critical COVID-19 and found lower mortality with thymosin alpha-1 (risk ratio 0.59), but results varied widely between studies (I squared 84%), there was no difference in the need for a ventilator or in hospital stay, and the authors said randomized trials were still needed to confirm it.
Bottom line: Weak, inconsistent evidence in hospitalized COVID-19; not confirmed by large randomized trials.
How it works
How to take it
What to track
Bottom line: No approved dose exists; trials used 1.6 mg injections on study-specific schedules under medical supervision.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Immune reactions and impurities in compounded or unregulated products: FDA has said compounded drugs containing thymosin alpha-1 may pose significant risk for immunogenicity (the body reacting against the peptide) for certain routes of administration and may have complexities with regard to peptide-related impurities and characterization of the active ingredient, and that the safety information is inadequate for the agency to sufficiently understand the extent of any safety issues. FDA lists it among substances whose nominations for compounding were later withdrawn.
Unknown contents: there is no FDA-approved thymosin alpha-1 product in the US, so vials sold online (including those labeled for research) have no verified identity, dose, sterility or purity. FDA says compounding from bulk drug substances (raw active ingredients) presents risks to patients and urges even licensed compounders to know their supplier.
Who should avoid it
- Anyone considering self-injecting products bought online, because FDA has said the available safety information is inadequate
- People with sepsis, severe pancreatitis or other serious illness who might use it instead of hospital care: the largest trials found no benefit on survival or infection
Pregnancy & breastfeeding
Pregnancy: we found no human data on thymosin alpha-1 in pregnancy, and FDA has said the safety information for it is inadequate. Breastfeeding: we found no data on whether it passes into breast milk. Anyone who is pregnant, could become pregnant or is breastfeeding should talk with their doctor before considering it, including in a trial.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is thymosin alpha-1 FDA-approved?⌄
No. Drugs@FDA lists no approved product containing it, and it is not a dietary supplement. It has been sold under the brand Zadaxin in other countries, mainly for hepatitis B; reviews from 2002 and 2009 described approvals in many countries in Asia and Latin America, but those are older lists and we could not confirm the current approvals on a regulator's website. In the US it is only available in clinical trials.
Is it legal to buy thymosin alpha-1 online?⌄
Products sold online as thymosin alpha-1 or TA-1 are not FDA-approved drugs, and labeling a vial for research does not make it approved or verified for people. FDA lists thymosin alpha-1 among substances it had flagged for significant safety risks in compounding (immune reactions and impurities) whose nominations for its compounding lists were later withdrawn. Talk with your doctor before using any product like this.
Does thymosin alpha-1 boost the immune system?⌄
It changes immune cell activity in laboratory studies, but that has not translated into clear benefits in the largest human trials. In 1,089 adults with sepsis it did not lower deaths, and in 508 patients with severe pancreatitis it did not prevent infection. No trial has tested it for general immune support in healthy people.
Does it help with long COVID or COVID-19?⌄
A 2023 meta-analysis of hospitalized patients with moderate to critical COVID-19 found lower deaths, but the studies disagreed widely and the authors called for randomized trials. We found no published trial in long COVID. A US phase 1 study (NCT06821100) is testing whether it improves COVID-19 booster responses in adults aged 65 and older; it was still recruiting in 2026 and has posted no results.
Can I take it with my supplements or medicines?⌄
No interaction studies have been published, and this page lists no known interactions, which is not the same as proof of safety. Anyone taking other medicines, including cancer treatment or medicines that affect the immune system, should have a doctor or pharmacist review their full list before any use, including in a trial.
References by claim
Track Thymosin Alpha-1 with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.
